$IBIO

Ibio Unveils Promising Data For IBIO-600 And Activin E Antibody, Enhancing Cardiometabolic And Obesity Treatment Options

$IBIO IBio, Inc. (Nasdaq:IBIO) has recently shared compelling data from its latest pharmacokinetics study on IBIO-600, a novel long-acting anti-myostatin…